US EditionObesity drug prices are dropping, but getting a steady supply remains a challenge
UNITED STATES AND UNITED KINGDOM, JUL 7 – Drug prices for obesity treatments like Wegovy and Zepbound have declined due to competition and new developments, but supply shortages and uneven insurance coverage keep access limited.
- On July 1, CVS Health's PBM dropped Zepbound from its formulary as prices for Wegovy and Zepbound fell to around $500 monthly, but access remains inconsistent.
- Rising competition from pill versions and complex manufacturing challenges explain the recent price drops and ongoing supply constraints for GLP-1 injectable obesity drugs.
- Despite falling prices, partial insurance coverage leads to hundreds of dollars in monthly costs for patients and some large employers dropping drug coverage, says Dr. Beverly Tchang.
- Upcoming pill versions from Novo Nordisk and Eli Lilly may arrive within a year, further lowering injectable drug prices and shifting market dynamics, experts say.
71 Articles
71 Articles
Who Is a Good Candidate for Weight Loss Medication?
Today, we have a variety of weight loss medications that can facilitate faster and more consistent weight loss. For overweight and obese individuals at risk for various health complications, this is a tremendous relief. But who exactly qualifies as a good candidate for weight loss medication? And what are the appropriate ways to use it?
Obesity Drug Prices Are Dropping, but Getting a Steady Supply Remains a Challenge
(MedPage Today) -- Prices are falling for the popular obesity treatments semaglutide (Wegovy) and tirzepatide (Zepbound), but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without...
Obesity drug prices fall, but access lags
KEY TAKEAWAYS: Wegovy and Zepbound prices have dropped to ~$500/month Insurance coverage is inconsistent, especially for Medicare/Medicaid Compounded alternatives remain in legal and safety gray zones Pill versions in development could drive prices lower Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for tho…
Wegovy and Zepbound prices are dropping, but steady access to the weight-loss drugs remains a challenge
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.The medications still amount to around $500 per month for those without insurance—out of reach for many patients. And even for people with insurance, coverage remains uneven.“The medications should be available, the question is at what price and can people sustain that,” said Matt Maciejewski, a Duke University professor …
Coverage Details
Bias Distribution
- 71% of the sources are Center
To view factuality data please Upgrade to Premium
